FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W53086736> ?p ?o ?g. }

• W53086736 endingPage "B4411" @default.
• W53086736 startingPage "B4411" @default.
• W53086736 abstract "Cell based therapy for ischemic heart disease has the potential to reduce post infarct heart failure and chronic ischemia. Treatment with granulocyte-colony stimulating factor (G-CSF) mobilizes cells from the bone marrow to the peripheral blood. Some of these cells are putative stem or progenitor cells. G-CSF is injected subcutaneously. This therapy is intuitively attractive compared to other cell based techniques since repeated catheterizations and ex vivo cell purification and expansion are avoided. Previous preclinical and early clinical trials have indicated that treatment with G-CSF leads to improved myocardial perfusion and function in acute or chronic ischemic heart disease. The hypothesis of this thesis is that patient with ischemic heart disease will benefit from G-CSF therapy. We examined this hypothesis in two clinical trials with G-CSF treatment to patients with either acute myocardial infarction or severe chronic ischemic heart disease. In addition, we assed a number of factors that could potentially affect the effect of cell based therapy. Finally, we intended to develop a method for in vivo cell tracking in the heart. Our research showed that subcutaneous G-CSF along with gene therapy do not improve myocardial function in patients with chronic ischemia despite a large increase in circulation bone marrow-derived cells. Also, neither angina pectoris nor exercise capacity was improved compared to placebo treatment. We could not identify differences in angiogenic factors or bone marrow-derived cells in the blood that could explain the neutral effect of G-CSF. Next, we examined G-CSF as adjunctive therapy following ST segment elevation myocardial infarction. We did not find any effect of G-CSF neither on the primary endpoint--regional myocardial function--nor on left ventricular ejection fraction (secondary endpoint) compared to placebo treatment. In subsequent analyses, we found significant differences in the types of cells mobilized from the bone marrow by G-CSF. This could explain why intracoronary injections of unfractionated bone marrow-derived cells have more effect that mobilization with G-CSF. A number of other factors could explain the neutral effect of G-CSF in our trial compared to previous studies. These factors include timing of the treatment, G-CSF dose, and study population. It is however, remarkable that the changes in our G-CSF group are comparable to the results of previous non-blinded studies, whereas the major differences are in the control/placebo groups. We found that ejection fraction, wall motion, edema, perfusion, and infarct size all improve significantly in the first month following ST-segment myocardial infarction with standard guideline treatment (including acute mechanical revascularization), but without cell therapy. This is an important factor to take into account when assessing the results of non-controlled trials. Finally, we found that ex vivo labeling of cells with indium-111 for in vivo cell tracking after intramyocardial injection is problematic. In our hand, a significant amount of indium-111 remained in the myocardium despite cell death. It is difficult to determine viability of the cells after injection in human trials, and it is thus complicated to determine if the activity in the myocardium tracks viable cells. Cell based therapy is still in the explorative phase, but based on the intense research within this field it is our hope that the clinical relevance of the therapy can be determined in the foreseeable future. Ultimately, this will require large randomized, double-blind and placebo-controlled trials with hard clinical endpoints like mortality and morbidity." @default.
• W53086736 created "2016-06-24" @default.
• W53086736 creator A5068022960 @default.
• W53086736 date "2012-03-01" @default.
• W53086736 modified "2023-09-29" @default.
• W53086736 title "Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease." @default.
• W53086736 cites W110203898 @default.
• W53086736 cites W111458436 @default.
• W53086736 cites W132415650 @default.
• W53086736 cites W1465829142 @default.
• W53086736 cites W1495287184 @default.
• W53086736 cites W1499075785 @default.
• W53086736 cites W1501089098 @default.
• W53086736 cites W1509136795 @default.
• W53086736 cites W1569560733 @default.
• W53086736 cites W1586414724 @default.
• W53086736 cites W1586474677 @default.
• W53086736 cites W1587857330 @default.
• W53086736 cites W1631250427 @default.
• W53086736 cites W1639419362 @default.
• W53086736 cites W173795208 @default.
• W53086736 cites W1756519908 @default.
• W53086736 cites W1768713563 @default.
• W53086736 cites W1782699038 @default.
• W53086736 cites W1963744446 @default.
• W53086736 cites W1963851116 @default.
• W53086736 cites W1964063165 @default.
• W53086736 cites W1965510231 @default.
• W53086736 cites W1965706789 @default.
• W53086736 cites W1967035072 @default.
• W53086736 cites W1968539943 @default.
• W53086736 cites W1969855616 @default.
• W53086736 cites W1969954863 @default.
• W53086736 cites W1969959647 @default.
• W53086736 cites W1970477123 @default.
• W53086736 cites W1970736113 @default.
• W53086736 cites W1970840945 @default.
• W53086736 cites W1971598822 @default.
• W53086736 cites W1973113569 @default.
• W53086736 cites W1973374695 @default.
• W53086736 cites W1973760359 @default.
• W53086736 cites W1974132609 @default.
• W53086736 cites W1974812650 @default.
• W53086736 cites W1974989261 @default.
• W53086736 cites W1975677393 @default.
• W53086736 cites W1976291192 @default.
• W53086736 cites W197648304 @default.
• W53086736 cites W1977401018 @default.
• W53086736 cites W1977437881 @default.
• W53086736 cites W1978227996 @default.
• W53086736 cites W1978238305 @default.
• W53086736 cites W1979202247 @default.
• W53086736 cites W1979670158 @default.
• W53086736 cites W1979993133 @default.
• W53086736 cites W1980039759 @default.
• W53086736 cites W1980772641 @default.
• W53086736 cites W1982688102 @default.
• W53086736 cites W1982861439 @default.
• W53086736 cites W1985164695 @default.
• W53086736 cites W1985395658 @default.
• W53086736 cites W1986410924 @default.
• W53086736 cites W1986691722 @default.
• W53086736 cites W1987503760 @default.
• W53086736 cites W1987865896 @default.
• W53086736 cites W1988377666 @default.
• W53086736 cites W1989013354 @default.
• W53086736 cites W1990224341 @default.
• W53086736 cites W1990357530 @default.
• W53086736 cites W1990736647 @default.
• W53086736 cites W1991317904 @default.
• W53086736 cites W1991889240 @default.
• W53086736 cites W1992800340 @default.
• W53086736 cites W1993327296 @default.
• W53086736 cites W1993414272 @default.
• W53086736 cites W1993757712 @default.
• W53086736 cites W1993966328 @default.
• W53086736 cites W1994322982 @default.
• W53086736 cites W1995485664 @default.
• W53086736 cites W1995598503 @default.
• W53086736 cites W1995748586 @default.
• W53086736 cites W1996280937 @default.
• W53086736 cites W1998941039 @default.
• W53086736 cites W1999007004 @default.
• W53086736 cites W1999579644 @default.
• W53086736 cites W2000619105 @default.
• W53086736 cites W2001835316 @default.
• W53086736 cites W2002111141 @default.
• W53086736 cites W2002868143 @default.
• W53086736 cites W2002910301 @default.
• W53086736 cites W2003996125 @default.
• W53086736 cites W2004114486 @default.
• W53086736 cites W2004814040 @default.
• W53086736 cites W2005039368 @default.
• W53086736 cites W2005120428 @default.
• W53086736 cites W2005971799 @default.
• W53086736 cites W2006194747 @default.
• W53086736 cites W2008004968 @default.
• W53086736 cites W2008152614 @default.

• next